WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205553
Description: NKTR-105 is a novel form of docetaxel that was developed using Nektar's advanced polymer technology platform. The compound belongs to the taxoid family and acts by disrupting the microtubular network in cells. It is being developed as an anti-neoplastic agent, and is the company's second oncology program in clinical development. In previous preclinical studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained therapeutic levels of docetaxel without the myelosuppression that is a dose-limiting toxicity for this widely-used cancer therapy. (Sourced from http://ir.nektar.com/releasedetail.cfm?releaseid=378943)
MedKoo Cat#: 205553
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: NKTR105; NKTR-105; NKTR 105; docetaxel conjugate.
IUPAC/Chemical Name: NONE
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
NKTR-105 is a polymer-conjugated docetaxel, currently being developed by Nektar. NKTR-105 is expected to improve the pharmacokinetic profile of the drug, resulting in prolonged exposure of the tumor to docetaxel and an improved time-concentration profile. Additionally, it is expected to enable higher therapeutic concentrations of the drug to be achieved and sustained over a longer period with a lower dose than the parent molecule, so as to potentially yield an enhanced therapeutic effect and improved tolerability. NKTR-105 is in a Phase 1 clinical trial in patients with certain types of solid tumors including hormone-refractory prostate cancer. Docetaxel is the only chemotherapeutic agent approved for use in five different cancer indications. It also could be explored as a therapy for breast, non-small cell lung, gastric, head and neck cancers. Each year, an estimated 3 million patients worldwide have been diagnosed with one of these types of cancer. (source: http://www.nektar.com/product_pipeline/oncology_nktr-105.html).
Current developer: Nektar Therapeutics, Inc.